Results 131 to 140 of about 6,249,776 (240)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Чемамюлл: ÑвÑÑ‰ÐµÐ½Ð½Ð°Ñ Ñ‚Ñ€Ð°Ð´Ð¸Ñ†Ð¸Ñ Ð²Ñ‹Ð¶Ð¸Ð²Ð°Ð½Ð¸Ðµ и Ñимвол культурного ÑÐ¾Ð¿Ñ€Ð¾Ñ‚Ð¸Ð²Ð»ÐµÐ½Ð¸Ñ Ð¼Ð°Ð¿ÑƒÑ‡Ðµ

open access: yes, 2019
This essay presents preliminary results of an ethnographic and descriptive research on the Mapuche statuary known as chemamüll together with the first record on its identification and its current territorial dispersio in the Araucania Region.
Saavedra, José, Salas Olave, Eugenio
core  

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

open access: yesMolecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller   +17 more
wiley   +1 more source

НАУЧНИОТ ТРУД - Да се напише и да се објави

open access: yes, 2015
Книгава ÐÐУЧÐИОТ ТРУД - Да Ñе напише и да Ñе објави претÑтавува збир од Ñознанија, препораки и забелешки на кои наидував низ моите триеÑет годР...
Спироски, Мирко
core  

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

open access: yesMolecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad   +35 more
wiley   +1 more source

Ðрхивы иÑтории, архивы памÑти. Графика ÐоÑми ЭÑканделла

open access: yes, 2019
The aim is of this research is to reconstruct the poetic and political discourse of plastic artist Noemí Escandell (1942-2019) by analyzing the formats, use of photographic archives and narrative thickness of her works created by the end of the sixties ...
Lucero, María Elena
core  

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola   +12 more
wiley   +1 more source

ИÑпитување на концентрациониот механизам за пертехнетат во тиреоидеата, плунчаните жлезди и желудникот кај Ñтаорец

open access: yes, 2016
The pertechnetate concentrating mechanism in thyroid gland, salivary glands and stomach was studied in rats by determination tissue: plasma radioactivity ratio.
Радуловиќ (Radulovikj), ВеÑна (Vesna)   +2 more
core  

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

open access: yesMolecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy